BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 954 filers reported holding BAXTER INTL INC in Q1 2014. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $279,466 | -45.0% | 7,405 | -33.6% | 0.01% | -43.8% |
| Q2 2023 | $508,359 | +53.3% | 11,158 | +36.5% | 0.02% | +45.5% |
| Q1 2023 | $331,578 | +33.7% | 8,175 | +112.2% | 0.01% | +120.0% |
| Q2 2022 | $248,000 | -25.3% | 3,853 | -10.0% | 0.01% | -54.5% |
| Q1 2022 | $332,000 | -15.3% | 4,281 | -6.3% | 0.01% | -8.3% |
| Q4 2021 | $392,000 | +93.1% | 4,571 | +81.2% | 0.01% | +20.0% |
| Q3 2021 | $203,000 | -5.1% | 2,523 | -5.2% | 0.01% | -23.1% |
| Q4 2020 | $214,000 | +1.4% | 2,662 | +8.5% | 0.01% | -31.6% |
| Q2 2020 | $211,000 | -89.0% | 2,453 | -90.6% | 0.02% | -96.4% |
| Q4 2014 | $1,919,000 | +6.7% | 26,178 | +4.5% | 0.53% | +4.5% |
| Q3 2014 | $1,798,000 | +0.6% | 25,053 | +1.3% | 0.51% | -2.7% |
| Q2 2014 | $1,788,000 | +0.8% | 24,726 | +2.5% | 0.52% | -8.7% |
| Q1 2014 | $1,774,000 | +10.3% | 24,114 | +4.3% | 0.58% | +11.0% |
| Q4 2013 | $1,608,000 | – | 23,126 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |